Skip to main content

Army photo

VIDEO ABOVE: New Shaped Trajectory Excalibur Round Changes Course in Flight, Destroys Tanks Hiding Under Bridges

By Kris Osborn - Warrior Maven

(Washington, D.C.) The Army Research Laboratory is vigorously pursuing technical innovations aimed at “discovering” and engineering new antibodies able to attach to and destroy Coronavirus, thereby helping those severely impacted with an infection, service scientists told Warrior.

The ARL work, done in tandem with the University of Texas in Austin, draws upon several elaborate emerging techniques intended to identify potentially “neutralizing” antibodies able to help, or even save, patients who are critically ill with COVID 19.

While no officially “neutralizing” antibodies have been discovered yet, there are a number of possibilities with potential promise; the work has inspired the eye and attention of senior Army leaders who oversee the services' scientific research, including the Commander of Army Futures Command, Gen. John Murray.

The ongoing work, intended to lead to the eventual production of COVID-19 antibodies, “has “identified 18 potential therapeutic/neutralizing monoclonal antibodies,” Murray said in an interview with Warrior.

Doctors and scientists draw blood from COVID 19-infected patients with the hope of “engineering” new antibody configurations able to destroy Coronavirus.

“We look to find sequences that are binding to COVID 19. Then we send them off to test their ability to neutralize. A neutralizing antibody keeps a pathogen from being able to proliferate. We assemble antibodies and select winners.” Dr. Jimmy Gollihar Synthetic Biology Research Scientist, U.S. Army Capabilities Development Command, Army Research Laboratory-South (University of Texas at Austin), Chief Technology Officer, Bioindustrial Manufacturing Innovation Institute, told Warrior in an interview about the process.

The goal, Gollihar explained, is to regenerate therapeutic antibodies and give doses to people who are critically ill to help them recover faster. The work is not intended to produce a long-term solution or cure but rather provide a “bridge to a vaccine,” he said.

Scroll to Continue

Recommended for You

Gollihar said that “antibody sequences are short-lived,” and do not provide permanent immunity. Antibodies have “varying degrees of half-life in a serum,” he added "A serum is passed over a column with immobilized antigens from the virus. Antibodies were then fragmenting so we had a library of B-Cells and we could correlate which antibodies were binding."

The antibodies are extracted from what Gollihar described as antibody-producing “B Cells” taken from the blood of infected patients.

“Antibodies were then fragmented, so we had a library from B-Cells and we could correlate which antibodies were binding, We have a number of candidates,” he said.

“In partnership with UT in Austin we’ve been working on methods to id sequences of heavy and light chains of antibodies that are specific to covid 19.The people that we drew blood from were recently infected. They range from one to two weeks post onset of symptoms. Once we drew their blood we separated their B Cells,” Gollihar said.

As for the process, Murray further explained that the ARL submitted a proposal to the National Institute for Innovation in Manufacturing Biopharmaceutical - Manufacturing Innovation Institute.

“The blood draws happened under UT supervision. When we pull all of the B Cells, we are pulling their full repertoire, everything they have. The challenge is to find antibodies that are binding to COVID 19. Once we find them we produce them and send them off to the lab,” Gollihar said.

Described as blood proteins, antibodies are made up of amino acids which make up proteins. Gollihar described proteins as “three-dimensional structures made up of a linear chain of amino acids, the building blocks of proteins. Amino acids are a composition of molecules or chemicals.”

ARL and University of Texas scientists plan to test the antibodies in a small group of infected individuals.

“We are not sure if they are neutralizing. We are working diligently to get through neutralization data and are in the process of moving some of those antibodies into production strains so we can test them,” Gollihar said.


Osborn previously served at the Pentagon as a Highly Qualified Expert with the Office of the Assistant Secretary of the Army - Acquisition, Logistics& Technology. Osborn has also worked as an anchor and on-air military specialist at national TV networks. He has appeared as a guest military expert on Fox News, MSNBC, The Military Channel and The History Channel. He also has a Masters Degree in Comparative Literature from Columbia University.

More Weapons and Technology -WARRIORMAVEN (CLICK HERE)